NeuroDerm CEO to Present at Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Neuroderm Ltd (NDRM) PT Raised to $70 at Cowen; Could Transform Late Stage Parkinson's Care
March 1, 2017 3:44 PM ESTCowen raised its price target on Neuroderm Ltd (NASDAQ: NDRM) to $70.00 (from $38.00) while maintaining a Outperform rating, saying it could transform late stage Parkinson's care.
Analyst Ken Cacciatore commented, "Neuroderm announced the preliminary Phase II results for ND0612H, and importantly, the... More
